Godavari Drugs
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Godavari Drugs' board approved working capital limits of up to Rs 34 crore from ICICI Bank at a meeting on 14 October 2026. The limits were sanctioned under a credit arrangement letter dated 12 October 2026 and will be secured as stipulated by the bank, with Managing Director Mukund Kakani authorised to execute the facility and security documents. The company manufactures active pharmaceutical ingredients and intermediates at a single site in Nanded, Maharashtra, and reported revenue of Rs 105.81 crore in the year to March 2026 after three straight years of decline. Total borrowings stood at Rs 76.36 crore at the end of March, with interest cover at 1.68 times and capital work in progress of Rs 56.54 crore for a new facility under production trials. It allotted shares and warrants to promoter-group investors in March 2026 at Rs 89 per share, raising Rs 44.12 crore.
Powered by Tijori
Godavari Drugs' board approved working capital limits of up to Rs 34 crore from ICICI Bank at a meeting on 14 October 2026. The limits were sanctioned under a credit arrangement letter dated 12 October 2026 and will be secured as stipulated by the bank, with Managing Director Mukund Kakani authorised to execute the facility and security documents. The company manufactures active pharmaceutical ingredients and intermediates at a single site in Nanded, Maharashtra, and reported revenue of Rs 105.81 crore in the year to March 2026 after three straight years of decline. Total borrowings stood at Rs 76.36 crore at the end of March, with interest cover at 1.68 times and capital work in progress of Rs 56.54 crore for a new facility under production trials. It allotted shares and warrants to promoter-group investors in March 2026 at Rs 89 per share, raising Rs 44.12 crore.
Powered by Tijori
Nov 15 (Reuters) - Godavari Drugs Ltd GDRU.BO:
ACCEPTED TO RELEASE PAYMENT OF 4.9 MILLION RUPEES FOR LEASE OF LAND
Source text for Eikon: ID:nBSE4DtP2z
Further company coverage: GDRU.BO
(([email protected];))
Nov 15 (Reuters) - Godavari Drugs Ltd GDRU.BO:
ACCEPTED TO RELEASE PAYMENT OF 4.9 MILLION RUPEES FOR LEASE OF LAND
Source text for Eikon: ID:nBSE4DtP2z
Further company coverage: GDRU.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Godavari Drugs do?
Godavari Drugs Ltd specializes in manufacturing and selling bulk drugs, including Pyrazinamide and Ethambutol HCL. They also offer contract manufacturing services.
Who are the competitors of Godavari Drugs?
Godavari Drugs major competitors are HR Hygiene Products, Kimia Biosciences, Lactose (India), Quest Laboratories, Natural Capsules, Panchsheel Organics, Bal Pharma. Market Cap of Godavari Drugs is ₹137 Crs. While the median market cap of its peers are ₹137 Crs.
Is Godavari Drugs financially stable compared to its competitors?
Godavari Drugs seems to be less financially stable compared to its competitors. Altman Z score of Godavari Drugs is 1.87 and is ranked 5 out of its 8 competitors.
Does Godavari Drugs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Godavari Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Godavari Drugs allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Capital Work in Progress, Inventory
How strong is Godavari Drugs balance sheet?
Balance sheet of Godavari Drugs is moderately strong, But short term working capital might become an issue for this company.
Is the profitablity of Godavari Drugs improving?
No, profit is decreasing. The profit of Godavari Drugs is ₹4.16 Crs for TTM, ₹4.38 Crs for Mar 2025 and ₹5.55 Crs for Mar 2024.
Is the debt of Godavari Drugs increasing or decreasing?
Yes, The net debt of Godavari Drugs is increasing. Latest net debt of Godavari Drugs is ₹61.85 Crs as of Mar-26. This is greater than Mar-25 when it was ₹59.6 Crs.
Is Godavari Drugs stock expensive?
Yes, Godavari Drugs is expensive. Latest PE of Godavari Drugs is 32.98, while 3 year average PE is 17.14. Also latest EV/EBITDA of Godavari Drugs is 20.03 while 3yr average is 10.88.
Has the share price of Godavari Drugs grown faster than its competition?
Godavari Drugs has given better returns compared to its competitors. Godavari Drugs has grown at ~-2.87% over the last 2yrs while peers have grown at a median rate of -18.0%
Is the promoter bullish about Godavari Drugs?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Godavari Drugs is 40.23% and last quarter promoter holding is 40.23%.
Are mutual funds buying/selling Godavari Drugs?
The mutual fund holding of Godavari Drugs is increasing. The current mutual fund holding in Godavari Drugs is 1.31% while previous quarter holding is 1.26%.